A Clinical Trial Of The Stat3 Inhibitor Pyrimethamine In Chronic Lymphocytic Leukemia

Conclusions❖ To determine whether STAT3 inhibition would confer clinical benefit in patients with CLL, we conducted a phase I clinical trial of continuous daily pyrimethamine, in the era before targeted therapy (enrollment 5/2010–4/2012), in relapsed CLL patients whose disease progressed despite standard therapies. ClinicalTrials. gov Identifier: NCT01066663